Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia
RSC Medicinal Chemistry · 2026 · 17 (4) · 2081-2095
DOI: 10.1039/d5md01005e ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Medicinal Chemistry, 2026. Verfasst von Ping Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizho…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Taishan Scholar Project of Shandong Province.
Abstract (Originalsprache)
A novel and selective ATR inhibitor, GBA-16-24 , was developed. It exhibits potent synthetic lethality in FLT3-mutated AML and synergizes with clinical FLT3 inhibitors, proposing a promising combination therapy.
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University Guiyang 550025 China wangmingliang@simm.ac.cn.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Zhongshan 528400 China ybzhou@simm.ac.cn jli@simm.ac.cn jiangkailong@zidd.ac.cn.
- Zhuhai Campus of Zunyi Medical University Zhuhai 519000 China.
- School of Pharmaceutical Sciences, Southern Medical University Guangzhou 510515 China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences Hangzhou 310024 China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery Yantai 264117 China.
ORCID-Profile: Yanyan Zhang, Mingliang Wang, Kailong Jiang
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Taishan Scholar Project of Shandong Province
Zitieren
APA
Li, P., Ren, H., Lan, X., Li, J., Liu, Z., Liu, H., Zheng, Z., Zeng, T., Wang, P., Sun, M., Xu, L., Zhang, Y., Zhou, Y., Li, J., Wang, M., & Jiang, K. (2026). Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia. RSC Medicinal Chemistry, 17(4), 2081-2095. https://doi.org/10.1039/d5md01005e
Vancouver
Li P, Ren H, Lan X, Li J, Liu Z, Liu H, et al. Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia. RSC Medicinal Chemistry. 2026;17(4):2081-2095. doi:10.1039/d5md01005e
BibTeX
@article{Li2026,
author = {Li, Ping and Ren, Haiyan and Lan, Xinyan and Li, Junfei and Liu, Zhi and Liu, Huashuo and Zheng, Zhijie and Zeng, Tianyan and Wang, Peili and Sun, Mingyang and Xu, Lei and Zhang, Yanyan and Zhou, Yubo and Li, Jia and Wang, Mingliang and Jiang, Kailong},
title = {Discovery of GBA-16-24 as a highly potent, selective ATR inhibitor for the treatment of FLT3-mutated acute myeloid leukemia},
journal = {RSC Medicinal Chemistry},
year = {2026},
volume = {17},
number = {4},
pages = {2081--2095},
doi = {10.1039/d5md01005e}
}
EUVIMED